Literature DB >> 15236405

Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations.

Pankaj B Agrawal1, Corinne D Strickland, Charles Midgett, Ana Morales, Daniel E Newburger, Melisa A Poulos, Kinga K Tomczak, Monique M Ryan, Susan T Iannaccone, Tom O Crawford, Nigel G Laing, Alan H Beggs.   

Abstract

Nemaline myopathy (NM) is the most common of several congenital myopathies that present with skeletal muscle weakness and hypotonia. It is clinically heterogeneous and the diagnosis is confirmed by identification of nemaline bodies in affected muscles. The skeletal muscle alpha-actin gene (ACTA1) is one of five genes for thin filament proteins identified so far as responsible for different forms of NM. We have screened the ACTA1 gene in a cohort of 109 unrelated patients with NM. Here, we describe clinical and pathological features associated with 29 ACTA1 mutations found in 38 individuals from 28 families. Although ACTA1 mutations cause a remarkably heterogeneous range of phenotypes, they were preferentially associated with severe clinical presentations (p < 0.0001). Most pathogenic ACTA1 mutations were missense changes with two instances of single base pair deletions. Most patients with ACTA1 mutations had no prior family history of neuromuscular disease (24/28). One severe case, caused by compound heterozygous recessive ACTA1 mutations, demonstrated increased alpha-cardiac actin expression, suggesting that cardiac actin might partially compensate for ACTA1 abnormalities in the fetal/neonatal period. This cohort also includes the first instance of an ACTA1 mutation manifesting with adult-onset disease and two pedigrees exhibiting potential incomplete penetrance. Overall, ACTA1 mutations are a common cause of NM, accounting for more than half of severe cases and 26% of all NM cases in this series.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236405     DOI: 10.1002/ana.20157

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  38 in total

1.  Clinical utility gene card for: nemaline myopathy.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

2.  Progressive external ophthalmoplegia as initial manifestation of sporadic late-onset nemaline myopathy.

Authors:  Oliver Wengert; Andreas Meisel; Wolfram Kress; Gabriele Dekomien; Klemens Angstwurm; Frank L Heppner; Hans-Hilmar Goebel; Werner Stenzel
Journal:  J Neurol       Date:  2010-11-12       Impact factor: 4.849

Review 3.  [Treatability of sporadic late onset nemaline myopathy].

Authors:  F Hanisch; I Schneider; T Müller; B F Romeike; G Stoltenburg; H J Holzhausen; S Zierz
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

4.  Association of a Novel ACTA1 Mutation With a Dominant Progressive Scapuloperoneal Myopathy in an Extended Family.

Authors:  Kristen Zukosky; Katherine Meilleur; Bryan J Traynor; Jahannaz Dastgir; Livija Medne; Marcella Devoto; James Collins; Jachinta Rooney; Yaqun Zou; Michele L Yang; J Raphael Gibbs; Markus Meier; Joerg Stetefeld; Richard S Finkel; Joachim Schessl; Lauren Elman; Kevin Felice; Toby A Ferguson; Ozge Ceyhan-Birsoy; Alan H Beggs; Gihan Tennekoon; Janel O Johnson; Carsten G Bönnemann
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

5.  Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1).

Authors:  Nigel G Laing; Danielle E Dye; Carina Wallgren-Pettersson; Gabriele Richard; Nicole Monnier; Suzanne Lillis; Thomas L Winder; Hanns Lochmüller; Claudio Graziano; Stella Mitrani-Rosenbaum; Darren Twomey; John C Sparrow; Alan H Beggs; Kristen J Nowak
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

6.  Clinical utility gene card for: Nemaline myopathy - update 2015.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

7.  Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy.

Authors:  Michaela Yuen; Sarah A Sandaradura; James J Dowling; Alla S Kostyukova; Natalia Moroz; Kate G Quinlan; Vilma-Lotta Lehtokari; Gianina Ravenscroft; Emily J Todd; Ozge Ceyhan-Birsoy; David S Gokhin; Jérome Maluenda; Monkol Lek; Flora Nolent; Christopher T Pappas; Stefanie M Novak; Adele D'Amico; Edoardo Malfatti; Brett P Thomas; Stacey B Gabriel; Namrata Gupta; Mark J Daly; Biljana Ilkovski; Peter J Houweling; Ann E Davidson; Lindsay C Swanson; Catherine A Brownstein; Vandana A Gupta; Livija Medne; Patrick Shannon; Nicole Martin; David P Bick; Anders Flisberg; Eva Holmberg; Peter Van den Bergh; Pablo Lapunzina; Leigh B Waddell; Darcée D Sloboda; Enrico Bertini; David Chitayat; William R Telfer; Annie Laquerrière; Carol C Gregorio; Coen A C Ottenheijm; Carsten G Bönnemann; Katarina Pelin; Alan H Beggs; Yukiko K Hayashi; Norma B Romero; Nigel G Laing; Ichizo Nishino; Carina Wallgren-Pettersson; Judith Melki; Velia M Fowler; Daniel G MacArthur; Kathryn N North; Nigel F Clarke
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

8.  Clinical heterogeneity in Korean patients with nemaline myopathy.

Authors:  Ji-Man Hong; Seung-Min Kim; Il-Nam Sunwoo; Se-Hoon Kim; Tai-Seung Kim; Dong-Suk Shim; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

9.  KLHL40 deficiency destabilizes thin filament proteins and promotes nemaline myopathy.

Authors:  Ankit Garg; Jason O'Rourke; Chengzu Long; Jonathan Doering; Gianina Ravenscroft; Svetlana Bezprozvannaya; Benjamin R Nelson; Nadine Beetz; Lin Li; She Chen; Nigel G Laing; Robert W Grange; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

10.  Phenotypes induced by NM causing alpha-skeletal muscle actin mutants in fibroblasts, Sol 8 myoblasts and myotubes.

Authors:  Drieke Vandamme; Ellen Lambert; Davy Waterschoot; Davina Tondeleir; Joël Vandekerckhove; Laura M Machesky; Bruno Constantin; Heidi Rommelaere; Christophe Ampe
Journal:  BMC Res Notes       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.